|
In a world first,
researchers at the Centre for Eye Research Australia (CERA) will
trial a new laser therapy aimed at stopping the progression of the
sight threatening disease, age-related macular degeneration (AMD).
Head of Macular
Research at CERA, Professor Robyn Guymer said the trial is
particularly exciting because unlike existing AMD treatments, the
laser therapy targets the disease in the early stages, before sight
is lost.
“Currently when a
patient is diagnosed with early AMD, they’re told that nothing can
be done until the disease reaches its late stages, by which time
some patients have suffered irreversible vision loss” Professor
Guymer said.
“In applying the
laser therapy we hope to halt, or partially reverse, the progression
of AMD before it threatens a patient’s sight”.
Professor Guymer said
the treatment involves a specially designed novel laser device that
delivers a controlled nanosecond dose of laser energy to the eye.
“Preliminary research
suggests that the application of retinal regeneration laser therapy
to the affected eye can eliminate the yellow deposits, known as ‘drusen’,
which are present in the retinal tissue of people with AMD” she
said.
“In eliminating the
drusen from a patient’s retina, we hope to reverse the degenerative
processes caused by the disease”.
“If successful, the
laser therapy will be a major breakthrough in AMD treatment and will
potentially benefit millions of people world-wide”.
AMD is a progressive
disease affecting the central area of the retina called the macula.
Fifteen per cent of people over 50, or half a million Australians,
live with the early stages of the disease. It is the leading cause
of vision loss in Australia and is estimated to cost the community
more than 2.6 billion dollars annually.
The Study, to be
conducted at the Royal Victorian Eye and Ear Hospital, will involve
50 patients with early AMD.
|